Framingham, Mass., April 21, 2005-- GTC Biotherapeutics, Inc. (Nasdaq: GTCB) ("GTC") announced today that its financial results for the first quarter 2005 will be released on Thursday, April 28, 2005 before the Nasdaq market opens. Geoffrey F. Cox, Ph.D., Chairman of the Board, Chief Executive Officer and President, will lead the call on April 28 starting at 10:00 a.m. Eastern Time to discuss these results and the Company's drug development progress. You may access the live internet broadcast or the subsequent archived recording, on GTC's website at http://www.gtc-bio.com or as follows: Live Call - In the United States, dial 1-800-638-4930
Outside the United States, dial 1-617-614-3944
Reference call ID: when prompted 54031719
Audio Archive - In the United States, dial 1-888-286-8010
Outside the United States, dial 1-617-801-6888
Reference call ID: when prompted 29586118
NOTE: a replay of the call will be available one hour following the end of the call and will be accessible until May 5, 2005.
The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).
GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATrynŽ, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Evaluation Agency for the use of ATrynŽ in patients with a hereditary antithrombin deficiency. In addition to the ATrynŽ program, GTC is developing a recombinant human albumin, a recombinant human alpha-1 antitrypsin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, http://www.gtc-bio.com.
CONTACT:
GTC Biotherapeutics
Thomas E. Newberry
Vice President, Corporate Communications
(508) 370-5374 Feinstein Kean Healthcare
Francesca DeVellis (investors)
Barbara Askjaer (media)
(617) 577-8110
Copyright 2006 GTC Biotherapeutics, All Rights Reserved